JP7494224B2 - ビアリールジアルキルホスフィンオキシドｆｐｒ２アゴニスト - Google Patents

ビアリールジアルキルホスフィンオキシドｆｐｒ２アゴニスト Download PDF

Info

Publication number
JP7494224B2
JP7494224B2 JP2021575327A JP2021575327A JP7494224B2 JP 7494224 B2 JP7494224 B2 JP 7494224B2 JP 2021575327 A JP2021575327 A JP 2021575327A JP 2021575327 A JP2021575327 A JP 2021575327A JP 7494224 B2 JP7494224 B2 JP 7494224B2
Authority
JP
Japan
Prior art keywords
halogen
hydrogen
haloalkyl
alkyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021575327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537350A5 (https=
JP2022537350A (ja
Inventor
スダカール シルデ，プラビン
クマール チャットパディヤイ，アミット
ケイ キック，エレン
アール ワーツ，ニコラス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2022537350A publication Critical patent/JP2022537350A/ja
Publication of JP2022537350A5 publication Critical patent/JP2022537350A5/ja
Application granted granted Critical
Publication of JP7494224B2 publication Critical patent/JP7494224B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021575327A 2019-06-18 2020-06-16 ビアリールジアルキルホスフィンオキシドｆｐｒ２アゴニスト Active JP7494224B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962862897P 2019-06-18 2019-06-18
US62/862,897 2019-06-18
PCT/US2020/037881 WO2020257161A1 (en) 2019-06-18 2020-06-16 Biaryl dialkyl phosphine oxide fpr2 agonists

Publications (3)

Publication Number Publication Date
JP2022537350A JP2022537350A (ja) 2022-08-25
JP2022537350A5 JP2022537350A5 (https=) 2023-06-21
JP7494224B2 true JP7494224B2 (ja) 2024-06-03

Family

ID=71409568

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021575327A Active JP7494224B2 (ja) 2019-06-18 2020-06-16 ビアリールジアルキルホスフィンオキシドｆｐｒ２アゴニスト

Country Status (7)

Country Link
US (1) US20220298186A1 (https=)
EP (1) EP3986903B1 (https=)
JP (1) JP7494224B2 (https=)
KR (1) KR102953013B1 (https=)
CN (1) CN114008059B (https=)
ES (1) ES2946673T3 (https=)
WO (1) WO2020257161A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102623473B1 (ko) * 2017-06-09 2024-01-09 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
CN113166134B (zh) 2018-11-26 2024-06-14 百时美施贵宝公司 作为甲酰肽2受体激动剂的吡咯烷酮衍生物
JP7802765B2 (ja) 2020-08-12 2026-01-20 ブリストル－マイヤーズ スクイブ カンパニー オキソピロリジン尿素ｆｐｒ２アゴニスト

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516566A (ja) 2003-01-23 2006-07-06 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング カルボキサミド誘導体及びその第Ｘａ因子の阻害剤としての使用
WO2018227065A1 (en) 2017-06-09 2018-12-13 Bristol-Myers Squibb Company Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
JP2018536687A (ja) 2015-12-10 2018-12-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト
WO2019173182A1 (en) 2018-03-05 2019-09-12 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516566A (ja) 2003-01-23 2006-07-06 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング カルボキサミド誘導体及びその第Ｘａ因子の阻害剤としての使用
JP2018536687A (ja) 2015-12-10 2018-12-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト
WO2018227065A1 (en) 2017-06-09 2018-12-13 Bristol-Myers Squibb Company Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
WO2019173182A1 (en) 2018-03-05 2019-09-12 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists

Also Published As

Publication number Publication date
ES2946673T3 (es) 2023-07-24
WO2020257161A1 (en) 2020-12-24
CN114008059B (zh) 2024-03-12
KR20220024551A (ko) 2022-03-03
EP3986903B1 (en) 2023-05-10
CN114008059A (zh) 2022-02-01
EP3986903A1 (en) 2022-04-27
US20220298186A1 (en) 2022-09-22
JP2022537350A (ja) 2022-08-25
KR102953013B1 (ko) 2026-04-14

Similar Documents

Publication Publication Date Title
TWI804585B (zh) 苯基吡咯啶酮甲醯肽2受體促效劑
KR102623473B1 (ko) 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
KR102772801B1 (ko) 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
JP7494224B2 (ja) ビアリールジアルキルホスフィンオキシドｆｐｒ２アゴニスト
JP7771157B2 (ja) オキソピロリジン ｆｐｒ２アゴニスト
KR20230084530A (ko) 아미노이미다졸 fpr2 효능제
HK40071411A (en) Phenylpyrrolidinone formyl peptide 2 receptor agonists
HK40035056A (en) Phenylpyrrolidinone formyl peptide 2 receptor agonists
HK40035056B (en) Phenylpyrrolidinone formyl peptide 2 receptor agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230613

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240409

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240423

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240522

R150 Certificate of patent or registration of utility model

Ref document number: 7494224

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150